QL Biopharm reports Phase 2 results of a monthly dose study evaluating zovaglutide, a novel, extended half-life GLP-1 receptor agonist at EASD 2025

Patients who received zovaglutide at a once-monthly dose of 160 mg experienced a 13.8% reduction in body weight at 24 weeks, highly comparable to reductions observed in patients who received 80 mg every other week (12.5%) The overall safety and tolerability of zovaglutide were consistent...